Cooper Companies FY25 & Q4 2025 slides: projects continued growth across segments

Cooper Companies (NYSE:COO) issued fiscal year 2025 guidance projecting total sales of $4.076-$4.096 billion, reflecting 4-4.5% organic growth, primarily driven by its CooperVision segment's anticipated 4-5% expansion. For Q4, the company forecasts sales of $1.049-$1.069 billion and non-GAAP EPS of $1.10-$1.14, indicating a slight moderation in organic growth from Q3's 5.7%. The positive outlook, supported by an expected $2 billion in free cash flow over the next three years, prompted a 1.76% after-hours stock rise, though the company acknowledges ongoing pricing pressures and competitive challenges.

Analysis

Cooper Companies (COO) has issued positive fiscal year 2025 guidance, projecting total sales between $4.076 billion and $4.096 billion, which translates to 4-4.5% organic growth. This outlook is built on the continued strength of its CooperVision segment, forecasted to grow 4-5%, outpacing the 3-3.5% growth expected from CooperSurgical. The guidance for the fourth quarter anticipates sales of $1.049 billion to $1.069 billion and non-GAAP EPS between $1.10 and $1.14. This Q4 organic growth forecast of 2-4% represents a slight moderation from the 5.7% year-over-year growth achieved in Q3, suggesting a potential normalization of growth rates. The company's financial position appears robust, underscored by a projection of approximately $2 billion in free cash flow over the next three fiscal years and a recent 70 basis point improvement in gross margin to 67.3%. Despite the positive outlook, which prompted a 1.76% after-hours stock increase, management has identified risks including pricing pressures in the Asia Pacific region, challenges in transitioning customers from Clarity to MyDay products, and broad industry competition. The stock's current price of $74.96 remains significantly below its 52-week high of $112.38, with analyst targets suggesting potential upside if the company successfully executes on its strategy.

Key Decisions for Investors

• Investors should view the solid FY25 guidance and strong free cash flow projection of $2 billion over three years as fundamental positives, with the stock's position well below its 52-week high potentially offering an attractive entry point.
• It is critical to monitor the execution of the MyDay product strategy and MiSight adoption, as these are the primary growth drivers underpinning the CooperVision segment's outperformance.
• Monitor Q4 organic growth and gross margin figures closely to gauge whether the projected growth moderation is temporary and to assess the company's ability to navigate identified pricing pressures, particularly in Asia.